Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Investor Relations

Corporate Profile

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor that we are evaluating in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. These programs and our broader development strategy are designed to target tumor vulnerabilities to overcome treatment resistance and deliver superior clinical benefit compared the SoC.

Company Overview (button) - September 17, 2022
Recent News
Sep 12, 2022

Next trial in RAS-mutated mCRC (ONSEMBLE) is a randomized Phase 2 trial to demonstrate onvansertib's contribution to SoC and position for a possible accelerated approval opportunity; topline data...

Sep 10, 2022

Durable responses to treatment, with a median duration of response (mDoR) of 11.7 months, reported in Phase 1b/2 clinical trial of onvansertib plus FOLFIRI/bevacizumab in second-line KRAS-mutated mCRC

Sep 8, 2022

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company...

More >

Stock Information
NASDAQCRDF
Contact Investor Relations

Direct     [USA +1] 858-952-7593
E-mail    ir@cardiffoncology.com

Contact

Events
September 14, 2022
8:00am - 5:00pm EDT

Cardiff Oncology management will be presenting and participating in 1x1 meetings at the H.C. Wainwright 24th Annual Global Conference on Wednesday, September 14th, 2022 at the Lotte New York...

September 13, 2022
8:00am - 5:00pm EDT

Cardiff Oncology management will be participating in a fireside chat and 1x1 meetings at the Baird Global Healthcare Conference on Tuesday, September 13th, 2022, at the InterContinental New York...

September 12, 2022
4:30pm - 5:30pm EDT

On Monday, September 12, 2022, Cardiff Oncology management will host a webcast and conference call to provide a clinical and corporate update. The event will feature discussions on the planned...